Our adept speaking faculty will arm you with proven strategies to facilitate benefit-risk counseling, optimize REMS operations through streamlined health system integration, leverage interoperable ...

A proactive strategy integrates advanced technology, predictive modeling, data-driven decision-making and adaptive ...

Abortion providers are in federal court in Charlottesville seeking to make the abortion pill mifepristone more accessible by ...

DelveInsight's "FILSPARI Market Size, Forecast, and Market Insight Report" highlights the details around FILSPARI, the first ...

It’s really important that we protect ... safe access to medication abortion no matter where people live — Virginia is ...

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

Professor Georgi Popov said safety assessment is typically done during the operational phase of projects, but that is ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

I think the operational challenges here are, first and foremost, training in myeloma—that bispecifics have a REMS program—a risk evaluation mitigation strategy. The providers need to be ...

This performance, coupled with upcoming growth and regulatory catalysts related to REMS (Risk Evaluation and Mitigation Strategy) and FSGS, could provide multiple opportunities for Travere to ...

Recent FDA updates in the areas of cardiac intervention, hypertension and arrhythmia disorders expand the pool of available ...